Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13993708 | 0.91 | HMGCR (0.45) | HMGCR | |
| SCHEMBL14544900 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4020679 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4901682 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL9274196 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4901679 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL4020685 | 0.88 | HMGCR (0.52) | HMGCR | |
| SCHEMBL16476432 | 0.85 | HMGCR (0.43) | HMGCR | |
| SCHEMBL15292130 | 0.85 | HMGCR (0.44) | HMGCR | |
| SCHEMBL13992372 | 0.83 | HMGCR (0.54) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459442-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459442-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080234248-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | SCHERING CORPORATION (US) | 2008-09-25 | — | — | US | disclosed |
| US-7368562-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368562-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7192944-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORP. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155674-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | HMGCR 29/4885 |
| US-20080234248-A1 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof | CYP46A1, NPC1L1, PCSK9 | HMGCR 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.